Review
Medicine, Research & Experimental
Carlos Jerjes-Sanchez, Hector Glenn-Valdez, Nayeli Zayas, Guillermo Cueto-Robledo, Liliana Bonola, Baltazar Pech-Alonso, Alicia Ramirez, Fernando Flores-Puente, Humberto Garcia-Aguilar, Guadalupe Espitia-Hernandez, Guillermo Prisciliano Montes, Tomas Pulido
Summary: Pulmonary arterial hypertension is a severe condition that greatly impacts patients' well-being and survival. Combined therapy with drugs like riociguat has shown better results.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Critical Care Medicine
Robert P. Baughman, Oksana A. Shlobin, Rohit Gupta, Peter J. Engel, Jeffrey Stewart, Elyse E. Lower, Franck F. Rahaghi, Joyce Zeigler, Steven D. Nathan
Summary: The study demonstrates the effectiveness of Riociguat in preventing clinical worsening and improving exercise capacity in patients with SAPH.
Article
Cardiac & Cardiovascular Systems
Franck F. Rahaghi, Maria Giovanna Trivieri, Sandeep Sahay
Summary: Effective clinical decision-making in the treatment of pulmonary arterial hypertension depends on various factors, including the patient's risk profile. Clinical trials suggest that switching from a PDE5i to riociguat can be beneficial for patients not achieving treatment goals. This review examines the clinical evidence for riociguat combination regimens and its role in upfront combination therapy and as an alternative to escalating therapy in PAH patients.
RESPIRATORY MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Jason Weatherald, Mitesh Thakrar, Rhea A. Varughese, Mithum Kularatne, Jonathan Liu, Lea Harper, Omid Kiamanesh, Nowell Fine, Evan Orlikow, Chidera Nwaroh, Christina Thornton, John Swiston, Lisa Kolkman, Nathan W. Brunner, Doug Helmersen, Naushad Hirani
Summary: This study suggests that the combination therapy of riociguat and ambrisentan has limited efficacy in initial treatment of pulmonary arterial hypertension (PAH) patients. After 4 months of treatment, pulmonary vascular resistance (PVR) decreased and other hemodynamic variables and risk scores improved.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2022)
Article
Pharmacology & Pharmacy
Yu-Yang Liu, Yi-Yang Qu, Shang Wang, Ci-Jun Luo, Hong-Ling Qiu, Hui-Ting Li, Ping Yuan, Lan Wang, Jin-Ling Li, Rong Jiang, Rui Zhang
Summary: This study evaluated the efficacy and safety of switching from phosphodiesterase-5 inhibitors (PDE-5is) to riociguat in patients with pulmonary arterial hypertension (PAH). The results showed that riociguat was more effective than PDE-5is in improving hemodynamic parameters, 6-minute walking distance (6MWD), World Health Organization functional class (WHO-FC), and cardiac index (CI). No adverse events were observed during the switch.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Medicine, General & Internal
Miaofa Ying, Jin Song, Shenglong Gu, Rui Zhao, Mingxing Li
Summary: The study confirmed that riociguat has better therapeutic effects in improving hemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) without inducing serious adverse events. Common adverse events of riociguat include dyspepsia and peripheral edema, with no other serious adverse reactions observed.
Review
Health Care Sciences & Services
Li Wang, Lu Zhu, Yong Wu, Qiwei Li, Hanmin Liu
Summary: The study found that riociguat therapy is safe and effective for patients with PAH and CTEPH, improving multiple hemodynamic parameters. However, it only has limited effects on other types of PH.
ANNALS OF PALLIATIVE MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Christoph B. Wiedenroth, Andreas Rolf, Kristin Steinhaus, Miriam S. D. Adameit, Steffen D. Kriechbaum, Moritz Haas, Fritz Roller, Christian W. Hamm, H. Ardeschir Ghofrani, Eckhard Mayer, Andreas Breithecker, Stefan Guth, Christoph Liebetrau
Summary: For patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), the combination therapy of riociguat and interventional balloon pulmonary angioplasty (BPA) has been found to significantly improve the prognosis. The 5-year follow-up results showed that patients receiving riociguat and BPA treatment had higher survival rates compared to those who did not receive specific treatment.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2023)
Article
Cardiac & Cardiovascular Systems
Raymond L. Benza, Hossein-Ardeschir Ghofrani, Ekkehard Grunig, M. Marius Hoeper, Pavel Jansa, Zhi-Cheng Jing, Nick H. Kim, David Langleben, Gerald Simonneau, Chen Wang, Dennis Busse, Christian Meier, Stefano Ghio
Summary: This post hoc analysis suggests that riociguat improves right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, with significant impact on long-term outcomes. Multiple parameters of right ventricular function were associated with survival and clinical worsening-free survival in the extension studies PATENT-2 and CHEST-2.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2021)
Article
Cardiac & Cardiovascular Systems
Theresa-Marie Dachs, Franz Duca, Rene Rettl, Christina Binder-Rodriguez, Daniel Dalos, Luciana Camuz Ligios, Andreas Kammerlander, Ekkehard Grunig, Ingrid Pretsch, Regina Steringer-Mascherbauer, Klemens Ablasser, Manfred Wargenau, Julia Mascherbauer, Irene M. Lang, Christian Hengstenberg, Roza Badr-Eslam, Johannes Kastner, Diana Bonderman
Summary: This study investigated the efficacy of riociguat, an oral soluble guanylate cyclase stimulator, in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The results showed that riociguat improved hemodynamics in PH-HFpEF but did not change clinical symptoms within the study period. There were some adverse events associated with riociguat, leading to more dropouts compared to placebo.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Marius M. Hoeper, Miguel-Angel Gomez Sanchez, Marc Humbert, David Pittrow, Gerald Simonneau, Henning Gall, Ekkehard Gruenig, Hans Klose, Michael Halank, David Langleben, Repke J. Snijder, Pilar Escribano Subias, Lisa M. Mielniczuk, Tobias J. Lange, Jean-Luc Vachiery, Hubert Wirtz, Douglas S. Helmersen, Iraklis Tsangaris, Joan A. Barbera, Joanna Pepke-Zaba, Anco Boonstra, Stephan Rosenkranz, Silvia Ulrich, Regina Steringer-Mascherbauer, Marion Delcroix, Pavel Jansa, Iveta Simkova, George Giannakoulas, Jens Klotsche, Evgenia Williams, Christian Meier, Hossein-Ardeschir Ghofrani
Summary: The EXPERT study monitored the long-term safety of riociguat in clinical practice, showing consistent safety with clinical trials and no new safety concerns, with a lower exposure-adjusted rate of hemoptysis/pulmonary hemorrhage compared to the Phase 3 trial in PAH.
RESPIRATORY MEDICINE
(2021)
Article
Pediatrics
Stefan Willmann, Andrea Kerstin Keller, Michaela Meyer, Dorina van Der Mey, Gabriela Wirsching, Yang Zhang, Henk-Jan Drenth, Anne Keunecke, Esmee Vendel, Soundos Saleh
Summary: The study investigated the safety and drug concentration of riociguat in children with pulmonary arterial hypertension. The results showed that the clearance and maintenance dose of the drug were different in children compared to adults, suggesting that a weight-adjusted dose should be used in children to achieve similar exposure as in adults.
PEDIATRIC PULMONOLOGY
(2023)
Article
Critical Care Medicine
Xavier Jais, Philippe Brenot, Helene Bouvaist, Mitja Jevnikar, Matthieu Canuet, Celine Chabanne, Ari Chaouat, Vincent Cottin, Pascal De Groote, Nicolas Favrolt, Delphine Horeau-Langlard, Pascal Magro, Laurent Savale, Gregoire Prevot, Sebastien Renard, Olivier Sitbon, Florence Parent, Romain Tresorier, Cecile Tromeur, Celine Piedvache, Lamiae Grimaldi, Elie Fadel, David Montani, Marc Humbert, Gerald Simonneau
Summary: This study compared the efficacy and safety of riociguat and balloon pulmonary angioplasty (BPA) in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The results showed that BPA was more effective in reducing pulmonary vascular resistance compared to riociguat, but had a higher incidence of treatment-related serious adverse events compared to riociguat.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Medicine, Research & Experimental
Qin-Hua Zhao, Su-Gang Gong, Jing He, Ping Yuan, Wen-Hui Wu, Ci-Jun Luo, Rong Jiang, Rui Zhang, Hong-Ling Qiu, Hui-Ting Li, Yuan Li, Jin-Ming Liu, Lan Wang
Summary: This study aims to compare the efficacy and safety of BPA combined with riociguat and riociguat monotherapy for inoperable CTEPH, with changes in pulmonary vascular resistance as the primary endpoint.
Article
Respiratory System
Mizuki Momoi, Takahiro Hiraide, Yoshiki Shinya, Hiromi Momota, Shogo Fukui, Michiyuki Kawakami, Yuji Itabashi, Keiichi Fukuda, Masaharu Kataoka
Summary: Triple oral combination therapy with macitentan, riociguat, and selexipag significantly improved clinical parameters and was well tolerated in patients with PAH. This combination could be particularly promising in low/intermediate-risk patients.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2021)
